Japan biopharmaceutical logistics market was valued at US$ 6.34 billion in 2024 and is expected to reach US$ 12.21 billion by 2033 at a CAGR of 7.77% during the forecast period 2025-2033.

Growth Driven by Advancements in Diagnostic Technologies and Rising Cancer Incidences Cancer pain remains one of the most challenging and prevalent issues for patients undergoing cancer treatment.

All products are independently selected by our editors. If you buy something, we may earn an affiliate commission. Learn how we test. Rejoice! It's finally time to put those 2025 fashion trends into ...

To make the world smarter, happier, and richer. Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches ...

Following its demutualization and IPO in 2010, Daiichi Life Group has transformed from one of Japan’s big four traditional life insurers to a multinational holding company with a multibrand ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

MS&AD Insurance Group Holdings Inc has reached a deal to sell its full equity holding in Challenger Ltd, an Australian annuities and investment management firm, to TAL Dai-ichi Life Australia Pty ...

Japanese life insurer Dai-ichi Life Holdings Inc. will take a 15.1% stake in an Australian life insurer Challenger. Archived articles are available to Magazine subscribers only. If you are already a ...

This year marks the 14th anniversary of the nuclear disaster at Japan’s Fukushima Dai-ichi nuclear power plant. On May 17, the No. 2 reactor unit at Pingtung County’s Ma-anshan Nuclear Power Plant is ...

However, there is a view that there is more to the transaction. The deal involved Dai-ichi buying the stake at $8.46 a share, outlaying about $884m, at a 53 per cent premium to Challenger’s ...